- Home
- GLPG vs STNG Comparison
GLPG vs STNG Comparison
Compare GLPG & STNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- STNG
- Stock Information
- Founded
- GLPG 1999
- STNG 2009
- Country
- GLPG Belgium
- STNG Monaco
- Employees
- GLPG N/A
- STNG N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- STNG Marine Transportation
- Sector
- GLPG Health Care
- STNG Consumer Discretionary
- Exchange
- GLPG Nasdaq
- STNG Nasdaq
- Market Cap
- GLPG 2.0B
- STNG 2.2B
- IPO Year
- GLPG 2005
- STNG 2010
- Fundamental
- Price
- GLPG $33.01
- STNG $45.70
- Analyst Decision
- GLPG Sell
- STNG Buy
- Analyst Count
- GLPG 4
- STNG 4
- Target Price
- GLPG $25.33
- STNG $60.50
- AVG Volume (30 Days)
- GLPG 372.1K
- STNG 1.2M
- Earning Date
- GLPG 07-23-2025
- STNG 07-30-2025
- Dividend Yield
- GLPG N/A
- STNG 3.51%
- EPS Growth
- GLPG N/A
- STNG N/A
- EPS
- GLPG N/A
- STNG 7.37
- Revenue
- GLPG $323,674,692.00
- STNG $916,164,000.00
- Revenue This Year
- GLPG $0.78
- STNG N/A
- Revenue Next Year
- GLPG N/A
- STNG $2.56
- P/E Ratio
- GLPG N/A
- STNG $6.12
- Revenue Growth
- GLPG 5.43
- STNG N/A
- 52 Week Low
- GLPG $22.36
- STNG $30.63
- 52 Week High
- GLPG $33.86
- STNG $77.83
- Technical
- Relative Strength Index (RSI)
- GLPG 67.37
- STNG 61.10
- Support Level
- GLPG $31.98
- STNG $43.40
- Resistance Level
- GLPG $33.66
- STNG $45.29
- Average True Range (ATR)
- GLPG 0.85
- STNG 1.61
- MACD
- GLPG 0.17
- STNG 0.09
- Stochastic Oscillator
- GLPG 88.39
- STNG 61.51
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.